A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Status:	Recruiting
Conditions:	Irritable Bowel Syndrome (IBS), Gastrointestinal
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	18 - 75
Updated:	3/1/2014
Start Date:	November 2013
Contact:	James Huber
Phone:	908-895-1213

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4
weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D
over the 4-week treatment period.

Inclusion Criteria:

- Ability to provide written informed consent

- Men or women aged 18-75 years

- Patient has IBS with diarrhea (IBS-D)

- Ability to communicate with the investigator

Exclusion Criteria:

- IBS with constipation (IBS-C) or mixed IBS (IBS-M)

- Other significant disease or condition that may interfere with trial completion

- Untreated lactose intolerance

- History of alcohol or drug abuse in past two years

- Participation in other clinical trials within prior month

We found this trial at

sites

PMG Research of Winston-Salem

1901 S Hawthorne Rd #306
Winston-Salem, North Carolina 27103

(336) 768-8062